# UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/uk-cost-utility-analysis-of-rituximab-in-patients-with-rheumatoid-arthritis-that/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Adrian Kielhorn,Duncan Porter,Α. Διαμαντόπουλος,Gavin Lewis |
| Citations | 58 |
| DOI | 10.1185/03007990802321683 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2148951322 |
| PMID | 18687164 |
| Type | article |
| Year | 2008 |

## Paper authors

- [Adrian Kielhorn](https://scholariq.org/researchers/adrian-kielhorn/)

## Paper journal

- [Current Medical Research and Opinion](https://scholariq.org/journals/current-medical-research-and-opinion/)

## Paper primary topic

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)

## Paper topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.